Cambridge Investment Research Advisors
TXG icon

Cambridge Investment Research Advisors’s 10x Genomics TXG Stock Holding History

Cambridge Investment Research Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Buy
112,788
+24,745
+28% +$648K 0.01% 1120
2026
Q1 		$1.87M Buy
88,043
+8,040
+10% +$161K ﹤0.01% 1639
2025
Q4 		$1.3M Buy
80,003
+21,984
+38% +$332K ﹤0.01% 1897
2025
Q3 		$678K Buy
58,019
+47,081
+430% +$614K ﹤0.01% 2383
2025
Q2 		$127K Sell
10,938
-15,628
-59% -$142K ﹤0.01% 3446
2025
Q1 		$232K Sell
26,566
-7,332
-22% -$92.4K ﹤0.01% 3089
2024
Q4 		$487K Buy
33,898
+2,498
+8% +$39.4K ﹤0.01% 2451
2024
Q3 		$709K Buy
+31,400
New +$649K ﹤0.01% 2130
2022
Q1 		– Sell
-1,458
Closed -$217K – 3314
2021
Q4 		$217K Buy
1,458
+48
+3% +$7.35K ﹤0.01% 2819
2021
Q3 		$205K Buy
1,410
+78
+6% +$13.4K ﹤0.01% 2796
2021
Q2 		$261K Buy
1,332
+69
+5% +$12.5K ﹤0.01% 2581
2021
Q1 		$229K Sell
1,263
-1,122
-47% -$194K ﹤0.01% 2500
2020
Q4 		$338K Buy
+2,385
New +$346K ﹤0.01% 2046

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cambridge Investment Research Advisors's TXG Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its 10x Genomics (TXG) stake by 28% in Q2 2026, buying an estimated $648K and bringing the position to 112,788 shares worth $4.32M. The position accounts for 0.01% of the portfolio, ranked #1120.

Cambridge Investment Research Advisors first reported a position in TXG in Q4 2020 and has held it in 13 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Cambridge Investment Research Advisors held 112,788 shares of 10x Genomics worth $4.32M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 24,745 10x Genomics shares in Q2 2026, an estimated $648K.
  • 10x Genomics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1120 holding.
  • Cambridge Investment Research Advisors first reported a position in 10x Genomics in Q4 2020 and has held it in 13 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.